Managing Neutropenia During Metastatic Triple-Negative Breast Cancer Treatment

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss practical strategies for preventing and managing neutropenia in patients with metastatic triple-negative breast cancer (mTNBC) receiving antibody-drug conjugate (ADC) therapy. NP Zafman reviews factors that may influence the use of primary versus secondary granulocyte colony-stimulating factor (G-CSF) prophylaxis, including patient age, comorbidities, prior history of neutropenia, infection risk, and individual clinical circumstances. The faculty also discuss laboratory monitoring, dose modifications, and the role of both long-acting and short-acting growth factor support to help patients maintain treatment intensity while minimizing the risk of febrile neutropenia. NP Stukus highlights practical considerations such as insurance coverage, treatment logistics, and patient preferences when selecting supportive care strategies. Together, the speakers emphasize that neutropenia management should be individualized and proactive, with the goal of minimizing treatment interruptions, maintaining dose intensity when appropriate, and optimizing outcomes for patients with metastatic triple-negative breast cancer.